Sameh Fikry
Impact in
- Nephrology top 2%
- Chronic Kidney Disease and Diabetes
- Renal Diseases and Glomerulopathies
-
- Diabetes Treatment and Management
- Hormonal Regulation and Hypertension
Papers in
-
- Chronic Kidney Disease and Diabetes 7
-
- Diabetes Treatment and Management 2
- Hormonal Regulation and Hypertension 1
Sameh Fikry
10 papers receiving 815 citations
Sameh Fikry's Hit Papers
Peers
Comparison fields: 5 of 39
- Nephrology 418
- Endocrinology, Diabetes and Metabolism 411
- Cardiology and Cardiovascular Medicine 88
- Pharmacology 24
- Pharmaceutical Science 11
Countries citing papers authored by Sameh Fikry
This map shows the geographic impact of Sameh Fikry's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sameh Fikry with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sameh Fikry more than expected).
Fields of papers citing papers by Sameh Fikry
This network shows the impact of papers produced by Sameh Fikry. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sameh Fikry. The network helps show where Sameh Fikry may publish in the future.
No co-authors to show.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial Hit paper breakdown → | 2019 | 244 |
| 2 | Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium–Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis Hit paper breakdown → | 2022 | 170 |
| 3 | Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial Hit paper breakdown → | 2023 | 149 |
| 4 | 2023 | 79 | |
| 5 | 2023 | 66 | |
| 6 | 2023 | 64 | |
| 7 | 2022 | 31 | |
| 8 | 2018 | 18 | |
| 9 | 2025 | 14 | |
| 10 | 2022 | 12 |
About Sameh Fikry
Sameh Fikry is a scholar working on Nephrology, Endocrinology, Diabetes and Metabolism, Cardiology and Cardiovascular Medicine, Nuclear Energy and Engineering and Waste Management and Disposal, having authored 10 papers that have together received 847 indexed citations. Recurring topics across this work include Chronic Kidney Disease and Diabetes (7 papers), Diabetes Treatment and Management (2 papers), Atrial Fibrillation Management and Outcomes (2 papers) and Hormonal Regulation and Hypertension (1 paper). The work is most often cited by research in Nephrology (418 citations), Endocrinology, Diabetes and Metabolism (411 citations), Cardiology and Cardiovascular Medicine (88 citations), Pharmacology (24 citations) and Pharmaceutical Science (11 citations). Sameh Fikry has collaborated with scholars based in United Kingdom and India. Their work appears in journals such as Diabetes Care, The Lancet Diabetes & Endocrinology, Clinical Research in Cardiology, Annals of Internal Medicine and The Lancet.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.